SNX-7081
SNX-7081 is an Hsp90 inhibitor with Ki and IC50 values of 26 nM and 44 nM, respectively. SNX-7081 blocks the nuclear translocation of NF-κB, inhibits the production of pro-inflammatory cytokines, attenuates the ERK/JNK and PDGF signaling pathways, and suppresses LPS (HY-D1056)-induced nitric oxide production. SNX-7081 inhibits DNA repair, induces G2/M cell cycle arrest, and triggers apoptosis via downregulation of MYC/nucleolin and activation of Fas. SNX-7081 can be used in research related to rheumatoid arthritis and cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 908111-22-8
- Formel: C24H31N3O3
- Molecular Weight:409.53
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
HSP90 26 nM (Ki) |
HSP90 44 nM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
14 nM
Compound: 34
|
Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
|
[PMID: 19552433] |
| A-375 | IC50 |
7 nM
Compound: 34
|
Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
|
[PMID: 19552433] |
| A-375 | IC50 |
9 nM
Compound: 34
|
Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| AU565 | IC50 |
16 nM
Compound: 34
|
Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
|
[PMID: 19552433] |
| AU565 | IC50 |
7 μM
Compound: 34
|
Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
|
[PMID: 19552433] |
| HCT-15 | IC50 |
61 nM
Compound: 34
|
Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| HT-29 | IC50 |
7 nM
Compound: 34
|
Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| K562 | IC50 |
3 nM
Compound: 34
|
Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| LNCaP | IC50 |
4 nM
Compound: 34
|
Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| MCF7 | IC50 |
10 nM
Compound: 34
|
Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| MDA-MB-231 | IC50 |
10 nM
Compound: 34
|
Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| MRC5 | CC50 |
24.93 μM
Compound: SNX-7081
|
Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay
|
[PMID: 22704890] |
| NCI-H460 | IC50 |
248 nM
Compound: 34
|
Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| PC-3 | IC50 |
14 nM
Compound: 34
|
Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| SK-MEL-5 | IC50 |
7 nM
Compound: 34
|
Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| SW-620 | IC50 |
6 nM
Compound: 34
|
Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
|
[PMID: 19552433] |
| Vero | CC50 |
12.94 μM
Compound: SNX-7081
|
Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 22704890] |
| Vero | EC50 |
1 μM
Compound: SNX-7081
|
Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
|
[PMID: 22704890] |
| Vero | EC50 |
1.03 μM
Compound: SNX-7081
|
Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
|
[PMID: 22704890] |
In Vitro
SNX-7081 (0.0001-10 μM; 6-24 h) inhibits the nuclear translocation of NF-κB, with an IC50 value of 114 nM in IL-1β-stimulated human umbilical vein endothelial cells, 241 nM in LPS-stimulated J774 mouse macrophages, 44 nM in IL-1β-stimulated rheumatoid arthritis synovial fibroblasts, and 88 nM in TNF-α-stimulated rheumatoid arthritis synovial fibroblasts[1].
SNX-7081 (6-24 h) potently suppresses the production of multiple proinflammatory cytokines in THP-1 human monocytes, human umbilical vein endothelial cells, and rheumatoid arthritis synovial fibroblasts, with an IC50 value as low as 13 nM; it also inhibits the proliferation of activated human umbilical vein endothelial cells with an IC50 of 3 nM, while exerting minimal effects on the proliferation of rheumatoid arthritis synovial fibroblasts[1].
SNX-7081 (0.001-10 μM; 24 h) inhibits growth factor-induced ERK-1/2 signaling pathway in human umbilical vein endothelial cells with an IC50 of 11 nM; inhibits IL-1β-induced JNK signaling pathway in human umbilical vein endothelial cells with an IC50 of 94 nM; inhibits PDGF-induced global tyrosine signaling pathway in NIH3T3 mouse fibroblasts with an IC50 of 56 nM; and also inhibits PDGF-induced ERK-1/2 signaling pathway in NIH3T3 mouse fibroblasts with an IC50 of 14 nM[1].
SNX-7081 (0.001-10 μM; 6 h) inhibits lipopolysaccharide (LPS)-induced nitric oxide production in J774 murine macrophages, with an IC50 of 6 nM[1].
SNX-7081 (100 nM; 48 h) induces extensive changes in protein expression in MEC1 cells, including significant downregulation of DNA replication and repair proteins, as well as upregulation of proteins related to energy metabolism and protein metabolism[2].
SNX-7081 (100 nM; 48 h) alters the levels of key regulatory proteins in MEC1 cells, including decreased expression of NFκB2 p52, MYC and BRCA1[2].
SNX-7081 (100 nM; 48 h) induces a slight increase in the DNA damage marker γH2AX in p53-mutant MEC1, MEC2 and U266 B-lymphoma cells[2].
SNX-7081 (100 nM; 48 h) induces extensive changes in protein expression in MEC1 cells, including upregulation of proteins related to DNA damage, epigenetic regulation and pro-apoptosis, as well as downregulation of proteins related to DNA replication and repair[2].
SNX-7081 (100 nM; 48 h) alters the levels of key regulatory proteins in MEC1 cells, including decreased expression of MYC, CCND1 and BRCA1[2].
SNX-7081 (100 nM; 48 h) synergistically increases the expression level of the DNA damage marker γH2AX in p53-mutated MEC1, MEC2 and U266 B-lymphocyte cancer cells[2].
SNX-7081 (72 h) potently inhibits the growth of human cancer cell lines including K562, A375, MCF-7, Hep-2, HepG2, A549, SW-620 and HeLa, with a mean IC50 of approximately 1 μM, while exhibits low cytotoxicity against human normal cell lines L-02, HDF and MRC5[3].
SNX-7081 (1 μM; 48 h) induces G2/M cell cycle arrest in K562, Hep-2, A549, SW-620 and HeLa human cancer cells, and exhibits stronger activity than SNX-2112 in K562, Hep-2 and A549 cells[3].
SNX-7081 (1 μM; 48 h) induces apoptosis in K562, A375, Hep-2, A549, SW-620 and HeLa human cancer cells, and exhibits stronger activity against K562, Hep-2 and A549 cells than SNX-2112[3].
SNX-7081 (1 μM; 0-48 h) reduces the expression of Hsp90 client proteins IKKα, CHK1, GSK3 and Raf-1 in human leukemia K562 cells in a time-dependent manner, and is more potent than SNX-2112[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human p53-negative MEC1 chronic lymphocytic leukemia cells
-
Concentration:100 nM
-
Incubation Time:48 h
-
Result:Significantly decreased NFκB2 p52 levels.
Significantly decreased MYC levels.
Significantly decreased BRCA1 levels.
Induced a non-significant increase in cyclin D1 (CCND1) levels.
-
Cell Line:human p53-negative MEC1 chronic lymphocytic leukemia cells
-
Concentration:100 nM (combined with 10 μM 2-FaraA)
-
Incubation Time:48 h
-
Result:Significantly decreased MYC levels.
Significantly decreased CCND1 levels.
Significantly decreased BRCA1 levels.
-
Cell Line:K562, Hep-2, A549, SW-620, HeLa
-
Concentration:1 μM
-
Incubation Time:48 h
-
Result:Induced G2/M phase cell cycle arrest in all tested cancer cell lines.
Increased the percentage of cells in G2/M phase to 22.6% (K562), 35.0% (Hep-2), 13.6% (A549), 27.0% (SW-620), and 17.6% (HeLa), compared to control levels of 3.1% (K562), 6.8% (Hep-2), 4.3% (A549), 7.4% (SW-620), and 10.7% (HeLa).
Was more effective at inducing G2/M arrest than SNX-2112 in K562, Hep-2, and A549 cells, but less effective in SW-620 and HeLa cells.
-
Cell Line:K562, A375, Hep-2, A549, SW-620, HeLa
-
Concentration:1 μM
-
Incubation Time:48 h
-
Result:Induced apoptosis in all 6 tested cancer cell lines.
Increased the percentage of apoptotic cells to 22.3% (K562), 48.7% (A375), 17.9% (Hep-2), 33.2% (A549), 16.7% (SW-620), and 13.8% (HeLa), compared to control levels of 4.0% (K562), 5.5% (A375), 7.5% (Hep-2), 11.8% (A549), 6.5% (SW-620), and 5.6% (HeLa).
Induced more apoptosis than SNX-2112 in K562, Hep-2, and A549 cells, but less apoptosis in SW-620 and HeLa cells.
-
Cell Line:K562
-
Concentration:1 μM
-
Incubation Time:0, 6, 12, 24, 48 h
-
Result:Reduced the expression of Hsp90 client proteins (IKKα, CHK1, GSK3, Raf-1) in a time-dependent manner.
Decreased protein levels to 11.7% (IKKα), 21.8% (CHK1), 5.8% (GSK3), and 10.4% (Raf-1) of control levels after 48 h of treatment.
Exerted stronger inhibitory effects on these client proteins than SNX-2112.
Chemical Information
-
CAS. Nr. 908111-22-8
-
Molecular Weight 409.53
-
Formel C24H31N3O3
-
SMILES
CC=1C2=C(N(C1)C3=CC(N[C@@H]4CC[C@@H](O)CC4)=C(C(N)=O)C=C3)CC(C)(C)CC2=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
[1]. Rice JW, et al. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008;58(12):3765-3775. [Content Brief]
[2]. Kaufman KL, et al. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget. 2015;6(38):40981-40997. [Content Brief]
[3]. Wang X, et al. Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells. Oncol Rep. 2015;33(1):230-238. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- SNX-7081
- 908111-22-8
- SNX7081
- SNX 7081
- HSP
- NF-κB
- ERK
- JNK
- PDGFR
- c-Myc
- DNA/RNA Synthesis
- Apoptosis
- chronic lymphocytic leukemia
- rheumatoid arthritis synovial fibroblasts
- rheumatoid arthritis
- human umbilical vein endothelial cells
- Jurkat cells
- THP-1 human monocytes
- Hsp70
- Hsp90
- J774 mouse macrophages
- Inhibitor
- inhibitor
- inhibit